A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2.This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.
Leave a Comment
You must be logged in to post a comment.